(CN) - A federal judge refused to toss Procaps' antitrust claims against collaborator Patheon, saying the drugmaker's alleged injuries are not self-inflicted simply because it "could have ducked the ...

Patheon, an Amsterdam-based contract drug developer, said in a regulatory filing it plans to raise $625 million in a public offering that analysts forecast would give the company a market value of ...

TORONTO and HIGH POINT, NC. – October 29, 2012 – Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, today announced ...

Contract drug manufacturer Patheon (TSX:PTI) has won two contracts valued at $18 million to make experimental type 2 diabetes drugs for German pharmaceutical company Boehringer Ingelheim. Research ...

Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully ...

DURHAM, NC--(Marketwired - March 04, 2015) - Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, announced it has ...

Patheon is awaiting finalization of a $7.2 billion deal that will make it a part of Thermo Fisher Scientific, but in the meantime the CDMO is moving forward with expansion plans at sites that stretch ...

TORONTO, Nov. 19, 2013 /CNW/ – Patheon Inc. (TSX:PTI) (“Patheon”) today announced that it has entered into an arrangement agreement (the “Arrangement Agreement”) with JLL/Delta Patheon Holdings, L.P., ...

DURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an ...

In response to the company accepting a buyout offer, shares of Patheon N.V. (NYSE: PTHN) , a provider of development and manufacturing services for the pharmaceutical industry, jumped 33% as of 10:45 ...